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RAAS Working Group Update 
The Renin-Angiotensin-Aldosterone System (RAAS) 
Working Group1 held its meeting in London during the sci-
entific sessions of the European Society of Hypertension in 
April 2012. The aim of the meeting was to review the data 
from ALTITUDE and the recent premature halt of this trial. 
This report summarises the main discussion points from 
this meeting.
The ALiskiren Trial In Type 2 diabetes Using cardiovas-
cular and renal Disease Endpoints (ALTITUDE) study was 
designed as a four-year, multicentre, randomised, placebo-
controlled trial that evaluated the efficacy of aliskiren 300 
mg daily versus placebo in high-risk patients suffering from 
type 2 diabetes mellitus and renal dysfunction whose blood 
pressure was normalized using one or more antihypertensive 
drugs (including RAAS inhibitors). Endpoints were cardio-
vascular and renal events. ALTITUDE was studying aliskiren 
on top of angiotensin-converting enzyme (ACE) inhibitor or 
angiotensin II type 1 receptor blocker (ARB) therapy, since 
this therapy is considered state-of-the-art in eligible patients.
The Data Safety Monitoring Board recommended in an 
interim analysis that it is unlikely that patients benefit from 
aliskiren on top of standard therapy and advised halting the 
trial. This came into effect in December 2011.
First, the outcomes of ALTITUDE were reviewed. 
Importantly, only 69% of all endpoints have officially been 
adjudicated, so these data should be considered as prelimi-
nary.2 Given these limitations, it nevertheless becomes 
clear that patients receiving aliskiren 300 mg daily experi-
enced an increased incidence of serious adverse events 
over 18 to 24 months of follow-up. Specifically, aliskiren 
treatment was associated with increased risk of nonfatal 
stroke (P<0.05), while there was a tendency toward more 
cardiovascular and total mortality, sudden death, nonfatal 
myocardial infarction, and hyperkalaemia and end-stage 
renal disease. This was accompanied by more frequent 
side effects, including hypotension, syncope, renal impair-
ment and drug discontinuation.
Second, a comparison was made versus preclinical stud-
ies investigating the blood pressure and renal effects of dual 
RAAS blockade, since these studies may provide insight 
into the physiological consequences of dual RAAS block-
ade with ACE inhibitor/ARB therapy and aliskiren. Studies 
in spontaneously hypertensive rats put on a low-sodium 
diet revealed that dual blockade rapidly caused a major 
decrease in blood pressure and severe renal failure which 
were accompanied by massive rises (up to several 100-
fold) in plasma renin and renal renin levels, thereby 
decreasing the angiotensinogen concentration in plasma.3 
These deleterious effects of dual RAAS blockade were pre-
vented by a high-salt diet. It was concluded that the obser-
vations in the low-salt-treated rats mirrored, at least in part, 
those in patients enrolled in ALTITUDE (Figure 1).
Moreover, studies in human cardiac tissue, obtained from 
patients undergoing cardiac transplantation4 or severe heart 
failure patients at the time of left ventricular assist device 
(LVAD) implantation,5 both being treated with (high) RAAS 
blocker doses, also revealed that renin levels in the human 
heart may rise >100-fold, thereby decreasing cardiac angio-
tensinogen. Interestingly, following LVAD implantation, 
renin levels dropped 10-fold, and cardiac angiotensinogen 
levels rose again, thus paradoxically allowing a rise in car-
diac angiotensin II levels5  (Figure 2). Therefore, it was put 
forward that a renin inhibitor like aliskiren, by diminishing 
cardiac renin activity, may also increase cardiac angio-
tensinogen and thus similarly increase cardiac angiotensin 
II, even when the majority of cardiac renin is blocked. This 
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Figure 1. The consequences of RAAS blockade under low- and high-salt conditions. Studies in hypertensive rats on a low-
sodium diet showed that dual RAAS blockade (combination of ACE inhibitor and ARB) causes extreme increases in plasma renin 
concentration, with associated decreases in plasma angiotensinogen (left panels). This is accompanied by severe hypotension with 
renal dysfunction (right panels). These effects are largely absent in rats fed a normal-high salt diet that have a neutral response to 
dual RAAS blockade. Adapted from2.
might be an unexpected ‘side-effect’ of aliskiren on top of 
other RAAS blockers that could explain, at least in part, the 
disappointing results from ALTITUDE.
Subsequently, data on the use of aliskiren in real-life 
treatment of hypertension (data from the Agenzia Italiana 
del Farmaco, the Italian Medicines Agency) were discussed. 
This web-based registry comprises data of >11,000 patients 
suffering from hypertension who received aliskiren and who 
were followed for at least six months.6 As indicated by the 
agency, aliskiren could be added only when blood pressure 
could not be controlled with the current drug regimens. Left 
ventricular hypertrophy, diabetes and renal disease were 
additional reasons for prescribing aliskiren. The results, 
obtained in all patients prescribed with aliskiren between 
March 2009 and May 2011, showed that the vast majority 
reached target blood pressure after addition of aliskiren. 
This observation was even more striking, as it was observed 
that in ~30% of the patients other antihypertensive drugs 
(diuretics, calcium channel blockers, beta blockers and ACE 
inhibitors) were stopped after the addition of aliskiren. 
Prespecified subanalyses in patients with coronary artery 
disease and type 2 diabetes mellitus showed similar results. 
Overall, tolerability and safety profile of aliskiren were 
favourable, and in this general hypertensive population only 
two serious adverse events (necessitating withdrawal of the 
drug) were reported. From these data it seems that aliskiren 
is a potent antihypertensive agent, and that addition of 
aliskiren apparently prompts physicians to reduce or even 
stop other antihypertensive agents.
In ALTITUDE, the median baseline systolic blood pres-
sure was 135 mm Hg, and thus blood pressure was already 
very well controlled. Probably, many patients may have 
become hypotensive when aliskiren 300 mg daily was 
added to their regimen. Of note, the inclusion criteria did 
not specify entry blood pressure, since not controlling 
blood pressure but protective effects by aliskiren were the 
objective. Thus, patients with low blood pressure could 
enter the study, which may not have been ideal. Furthermore, 
different from this real-life registry, patients in ALTITUDE 
clearly had no dose reduction or drug withdrawal when 
aliskiren was added. This treatment regimen, inherent to 
the ALTITUDE study protocol, could explain the excess 
number of adverse events in these high-risk diabetic 
patients with renal dysfunction.
Finally, the implications of ALTITUDE for the use of 
aliskiren in heart failure were reviewed. Dual RAAS 
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blockade has been studied extensively in heart failure, in 
particular the combination of ACE inhibitors and ARBs.7 
Although some studies hinted toward a reduction of heart 
failure hospitalisation, this was consistently associated with 
an increased incidence of renal dysfunction, hyperkalae-
mia, hypotension and drug discontinuation, which has off-
set the widespread use of this combination.8 As a 
consequence, the use of dual RAAS blockade is controver-
sial.9 There are several lines of evidence to suggest that 
renin inhibition might be effective in heart failure.10,11 
However, data on the use of aliskiren in heart failure are 
still limited. The Aliskiren Observation of Heart Failure 
Treatment (ALOFT) trial 12 reported good tolerability when 
aliskiren was added to standard therapy (including an ACE 
inhibitor), with beneficial effects on the surrogate efficacy 
outcome marker brain natriuretic peptide. The Aliskiren 
Study in Post-MI Patients to Reduce REmodeling (ASPIRE) 
study13 reported neutral effects of aliskiren on left ventricu-
lar remodelling in post-myocardial infarction heart failure 
when added on top of standard therapy. Yet, this was asso-
ciated with more (serious) side effects, thus contraindicat-
ing its use in combination with other RAAS blockers in 
post-myocardial infarction patients. Currently, two large 
studies testing aliskiren in heart failure are ongoing: the 
Aliskiren Trial of Minimizing OutcomeS for Patients with 
HEart failuRE (ATMOSPHERE) (chronic heart failure) 
and the Aliskiren Trial on Acute Heart Failure Outcomes 
(ASTRONAUT) (acute heart failure). In comparison with 
ALTITUDE, these trials differ considerably in patient char-
acteristics and in an active run-in period, and they have a 
treatment arm with aliskiren alone, as reviewed recently.14 
Furthermore, after ALTITUDE was stopped, recruitment 
for ATMOSPHERE and ASTRONAUT was temporarily 
halted, allowing a safety interim analysis. No major safety 
issues have come up, and to the best of our knowledge these 
trials are currently recruiting again.
Summary
The premature halting of ALTITUDE raises questions 
about the potential position of aliskiren (and other renin 
inhibitors)  as an additional RAAS-inhibitor in the treat-
ment of hypertension when present in diabetes together 
with renal and/or cardiovascular disease.
Figure 2. High tissue renin depletes tissue angiotensinogen. Studies were performed in cardiac tissue from patients treated with a 
left ventricular assist device (LVAD), pre- and post-implantation. Exceptionally high renin levels may deplete tissue angiotensinogen 
(upper panels). Upon recovery of the left ventricular function post-LVAD implantation, renin levels return to more physiological 
levels, and as a result tissue angiotensinogen stores recover with a paradoxical increase in angiotensin II (lower left panel). An inverse 
correlation between renin and angiotensinogen was observed (lower right panel). Adapted from3, 4. 
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From reviewing data from ALTITUDE and from experi-
mental data, it seems that aliskiren is a very potent antihy-
pertensive agent, in particular when administered in 
combination with other RAAS inhibitors and in low-sodium 
states. Patients in ALTITUDE were treated with optimal 
medication, including high-dose ACE inhibitors or ARBs, 
while blood pressure and sodium were well balanced. From 
experimental and observational data, we know that such 
subjects are particularly prone to the side effects of exces-
sive RAAS blockade.15
Furthermore, no standard dose reduction of other anti-
hypertensive agents was suggested in ALTITUDE, some-
thing commonly practised in the ‘real world’. The same 
data from aliskiren in the real world do not suggest an addi-
tional vulnerability in patients with type 2 diabetes mellitus 
or coronary artery disease. Finally, we have limited data in 
patients with heart disease and heart failure, where aliskiren 
could be of benefit.
Where do we stand with renin inhibition? From availa-
ble data, it seems that dual RAAS blockade in diabetic 
patients with reduced renal function on optimal treatment 
including full-dose ACE inhibitors or ARBs, is likely to 
cause side effects, while additional efficacy is questionable. 
Under such conditions, the use of aliskiren as a single agent 
to block the RAAS seems much more promising. In this 
light, it is reassuring to note that several studies that are part 
of the aliskiren clinical development program will compare 
aliskiren as a single RAAS inhibitor with another RAAS 
inhibitor. These studies are extremely important as they 
will provide insights in the efficacy of aliskiren, its safety 
and its potential future position in cardiovascular disease 
treatment.
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